TESARO Inc: Immunotherapy Pipeline In progress
Edison | Jun 11, 2014 02:19AM ET
TESARO Inc (NASDAQ:TSRO) presented detailed data of three Phase III trials of rolapitant (one for patients receiving moderately emetogenic chemotherapy [MEC] and two for highly emetogenic chemotherapy [HEC]), which reinforced the differentiated attributes of the product compared to other products in the same class. The company also announced two planned Phase III trials of Niraparib, bringing the total Phase III programmes to four for this drug.
TESARO presented detailed Phase III data of three trials (HEC1, HEC2 and MEC) at the 2014 ASCO (American Society of Clinical Oncology) annual meeting. These detailed data (top-line results were reported previously in press releases) continue to build a differentiated product profile for the drug: superb safety, long half-life (which translates into good efficacy) and multiple forms of administration (oral and IV).
h3 New Phase III trials planned for niraparib/h3TESARO announced two new Phase III trials of niraparib as a maintenance therapy, one in first-line ovarian cancer and another in first-line small cell lung cancer (SCLC). These two programmes bring the total Phase III programmes to four and could potentially make the drug eligible to 30,360-35,240 patients, significantly larger than the size of target patients covered by the previous two Phase III trials, platinum sensitive, relapsed high-grade serous ovarian cancer and germline BRCA mutation positive, advanced or metastatic breast cancer.
h3 Immunotherapy pipeline in progress/h3TESARO’s Immuno-oncology pipeline consists of five antibodies against various immune checkpoints at pre-clinical stages of development. Investigational new drug (IND)-enabling work has started for the lead candidate, anti-PD1 antibody TSR-042, which should enter clinical trials in mid-2015.
h3 Valuation: Still attractive with more upside in 2015/h3We have slightly lowered our valuation of TESARO to $1,806m, or $50.3/share from previously $1,831m, or $51.0/share, due to higher R&D cost estimates in 2014. Our valuation does not include any value of the early-stage immune checkpoint portfolio as the candidates are still in preclinical development or the two new niraparib indications as the trial accruals have not started yet.
Get The News You Want
To Read the Entire Report Please Click on the pdf File Below
/h3
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.